Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 987-991

  Fizazi, K ^a   Gravis, G ^b   Flechon, A ^c   Geoffrois, L ^d   Chevreau, C ^e   Laguerre, B ^f   Delva, R ^g   Eymard, J C ^h   Rolland, F ^g   Houede, N ⁱ   Laplanche, A ^a   Burcoveanu, D ^a   Culine, S ^j  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CENTRE LÉON BÉRARD   (France)

^d CENTRE ALEXIS VAUTRIN   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f CENTRE EUGÈNE MARQUIS   (France)

^g UMR INSERM U892 CNRS 6299

^h INSTITUT JEAN GODINOT   (France)

ⁱ INSTITUT BERGONIÉ   (France)

^j SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

chemotherapy; gemcitabine; germ cell tumor; salvage

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; GEMCITABINE; IFOSFAMIDE;

ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SALVAGE THERAPY; SECONDARY; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IFOSFAMIDE; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; PROSPECTIVE STUDIES; SALVAGE THERAPY; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921434958     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu099     Document Type: Article

References (33)

1. Beyer, J., Albers, P., Altena, R., et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24 (2013), 878–888.
2. Albers, P., Albrecht, W., Algaba, F., et al. EAU guidelines on testicular cancer: 2011 update. Eur Urol 60 (2011), 304–319 –.
3. The International Prognostic Factors Study Group, Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28 (2010), 4906–4911 –.
4. Einhorn, L.H., Williams, S.D., Chamness, A., et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357 (2007), 340–348.
5. Lorch, A., Bascoul-Mollevi, C., Kramar, A., et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 29 (2011), 2178–2184.
6. Pico, J.L., Rosti, G., Kramar, A., et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16 (2005), 1152–1159.
7. Lorch, A., Kleinhans, A., Kramar, A., et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol 30 (2012), 800–805.
8. Motzer, R.J., Geller, N.L., Tan, C.C., et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979–1989). Cancer 67 (1991), 1305–1310.
9. McCaffrey, J.A., Mazumdar, M., Bajorin, D.F., et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15 (1997), 2559–2563.
10. Lotz, J.P., Bui, B., Gomez, F., et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol 16 (2005), 411–418.
11. Bokemeyer, C., Gerl, A., Schoffski, P., et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17 (1999), 512–516.
12. Einhorn, L.H., Stender, M.J., Williams, S.D., Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17 (1999), 509–511 –.
13. Hinton, S., Catalano, P., Einhorn, L.H., et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20 (2002), 1859–18563 Erratum in: J Clin Oncol 2002; 20: 3754.
14. Kollmannsberger, C., Beyer, J., Liersch, R., et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensely pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 22 (2004), 108–114.
15. Pectasides, D., Pectasides, M., Farmakis, D., et al. Gemcitabine and Oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors. A phase II study. Ann Oncol 15 (2004), 493–497.
16. De Giorgi, U., Rosti, G., Aieta, M., et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory non-seminomatous germ cell tumor. Eur Urol 50 (2006), 1032–1038.
17. Bokemeyer, C., Oechsle, K., Honecker, F., et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 19 (2008), 448–453.
18. Van Moorsell, J., Pinedo, H.M., Veerman, G., et al. Mechanism of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80 (1999), 981–990.
19. Vadell-Nadal, C., Nogue-Aliguer, M., Fabregat-Mayol, X., et al. A phase II trial of the combination of gemcitabine, ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer. Lung Cancer 28 (2000), 109–115.
20. Boni, C., Bisagni, G., Savoldi, L., et al. Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC). Int J Cancer 87 (2000), 724–727.
21. Tognoni, A., Pensa, F., Vaira, F., et al. A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer. J Chemother 13 (2001), 202–205.
22. Mohedano Mohedano, N., Sanchez Rovira, P., Lozano Barriuso, A., et al. Triplet chemotherapy combination with gemcitabine, cisplatin and ifosfamide in patients with advanced non-small-cell lung cancer: phase II study. Am J Clin Oncol 26 (2003), 363–365.
23. Pagliaro, L.C., Millikan, R.E., Tu, S.M., et al. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20 (2002), 2965–2970.
24. Logothetis, C.J., Samuels, M.L., Trinidade, A., et al. The growing teratoma syndrome. Cancer 50 (1982), 1629–1635.
25. André, F., Fizazi, K., Culine, S., et al. The growing teratoma syndrome: results of therapy and long-term follow-up of a rare complication of non seminomatous germ-cell tumors. Eur J Cancer 36 (2000), 1389–1394.
26. Kondagunta, G.V., Bacik, J., Donadio, A., et al. Combination of paclitaxel, ifosfamide and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23 (2005), 6549–6555.
27. Fizazi, K., Culine, S., Droz, J.P., et al. Primary mediastinal non-seminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol 16 (1998), 725–732.
28. Fizazi, K., Culine, S., Kramar, A., et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22 (2004), 3868–3876.
29. Fizazi, K., Pagliaro, L., Flechon, A., et al. A phase III trial of personalized chemotherapy based on tumor marker decline in poor-prognosis germ-cell tumors (GCT): results of GETUG 13. J Clin Oncol, 31(suppl), 2013 abstr LBA4500.
30. Massard, C., Kramar, A., Beyer, J., et al. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Ann Oncol 24 (2013), 322–328.
31. Theodore, C.H., Terrier-Lacombe, M.J., Laplanche, A., et al. Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. Br J Cancer 90 (2004), 55–59.
32. Thibault, C., Fizazi, K., Barrios, D., et al. Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. Eur J Cancer 50:7 (2014), 1284–1290.
33. de Wit, R., Skoneczna, I., Daugaard, G., et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol 30 (2012), 792–799.